The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor StudiesBhavatarini Vangamudi, Jannik N. Andersen, Alessia Petrocchi et al.|Cancer Research|2015Cited by 275
Abstract 3528: The SMARCA2/4 catalytic activity, but not the bromodomain, is a drug target in SWI/SNF mutant cancersBhavatarini Vangamudi, Jannik N. Andersen, Thomas A. Paul et al.|Cancer Research|2015Cited by 0
Supplementary Figures 1 - 8 from The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor StudiesBhavatarini Vangamudi, Jannik N. Andersen, Thomas A. Paul et al.|Unknown|2023Cited by 0
Supplementary Methods, Figure Legends from The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor StudiesBhavatarini Vangamudi, Jannik N. Andersen, Thomas A. Paul et al.|Unknown|2023Cited by 0
Supplementary Figures 1 - 8 from The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor StudiesBhavatarini Vangamudi, Jannik N. Andersen, Thomas A. Paul et al.|Unknown|2023Cited by 0